Every GLP-1 Option Ranked by Price: Summer 2026 Edition

Twelve months ago, the GLP-1 pricing conversation was simple: brand-name was expensive, compounded was cheap. In summer 2026, the landscape is far more nuanced. Two new oral pills, a Medicare demonstration program, manufacturer self-pay programs, and a January 2027 list price cut have created a dozen distinct pricing pathways.

Here's every option, ranked by what you'll actually pay per month.

Complete Pricing Ranking: Cheapest to Most Expensive

The Medicare GLP-1 Bridge Explained

Starting July 1, 2026, eligible Medicare Part D beneficiaries can access Wegovy, Zepbound KwikPen, and Foundayo for a flat $50/month through the Medicare GLP-1 Bridge. Key details:

• Runs July 1, 2026 through December 31, 2027 (18 months)
• Covers three medications: Wegovy (all forms), Zepbound KwikPen, and Foundayo
• The $50 copay does not count toward your Part D deductible or out-of-pocket cap
• Requires prior authorization through Humana (the CMS central processor)
• Negotiated net manufacturer price: $245/month
• Not available for Medicaid or PACE program enrollees

The January 2027 Price Cut

Novo Nordisk announced in February 2026 that it will drop the list price of Wegovy, Ozempic, and Rybelsus to $675/month effective January 1, 2027. This represents:

• ~50% reduction for Wegovy (from $1,349)
• ~35% reduction for Ozempic (from $1,028)
• Applies to all doses, including Wegovy pills
• Does not affect self-pay DTC pricing through NovoCare

The practical impact: patients on high-deductible health plans or coinsurance-based designs will see meaningful savings. Patients using manufacturer self-pay programs won't see a change.

Compounded vs. Brand: The Cost Gap Is Narrowing

A year ago, the cost gap between compounded and brand was dramatic — $150/mo vs $1,000+/mo. Today, the picture looks different:

• At starter doses: Brand pills ($149) are now price-competitive with many compounded options
• At maintenance doses: Brand pills ($299) are still more expensive than the cheapest compounded providers ($99–$179), but the gap has narrowed from 10x to roughly 2x
• For Medicare patients: Brand at $50/mo is now cheaper than any compounded option
• The regulatory risk premium: Compounded providers face ongoing enforcement uncertainty, which brand-name options don't

How to Choose: A Decision Framework

If you're on Medicare: Wait for the GLP-1 Bridge (July 2026) — $50/mo for Wegovy, Zepbound, or Foundayo is the best deal in the market.

If you have commercial insurance that covers GLP-1s: Use the manufacturer savings card — $25/mo is unbeatable.

If you're self-pay and want FDA approval: Wegovy pill or Foundayo at $149/mo starter are the entry points. Foundayo has no food restrictions.

If cost is the primary driver: GobyMeds at $99/mo or Yucca at $146/mo (6-month plan) remain the most affordable options from verified providers.